+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Psoriatic Arthritis Therapeutics Market 2019-2023 - Product Image

Global Psoriatic Arthritis Therapeutics Market 2019-2023

  • ID: 4807760
  • Report
  • July 2019
  • Region: Global
  • 134 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc.
  • Celgene Corp.
  • Novartis AG
  • Pfizer Inc.
  • MORE
Global Psoriatic Arthritis Therapeutics Market: About this market

Psoriatic arthritis is an autoimmune disorder that primarily affects psoriasis patients, with approximately 30% of the patient population at risk. The psoriatic arthritis therapeutics market analysis considers sales from both biologics and small molecules. Our analysis also considers the sales of psoriatic arthritis therapeutics in Asia, Europe, North America, and ROW. In 2018, the biologics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as strong efficacy of approved drugs, availability of patient assistance programs, strong patient pool, and increasing awareness campaigns will play a significant role in the biologics segment to maintain its market position. Also, our global psoriatic arthritis therapeutics market report also looks at factors such as the dominance of biologics, growing awareness of psoriatic arthritis, and strong prevalence. However, difficulty in diagnosis, high treatment costs, and idiopathic nature of the disease may hamper the growth of the psoriatic arthritis therapeutics industry over the forecast period.

Global Psoriatic Arthritis Therapeutics Market: Overview

Dominance of biologics

The global psoriatic arthritis therapeutics market is expected to benefit significantly from the strong dominance of biologics during the forecast period. In 2018, over 80% of the market revenue was generated from the sales of biologics. As most of the drugs in the market have lost their patents, the market has witnessed an increase in the entry of biosimilars of major drugs. The entry of biosimilars has not resulted in the value erosion of the market as these biosimilars, despite being priced on the lower end, are still priced higher than the small molecule drugs approved in the market. Moreover, the high efficacy of biologics is resulting in high demand for biologic drugs, which is restricting the growth of small-molecule drugs. The dominance of biologics will lead to the expansion of the global psoriatic arthritis therapeutics market at a CAGR of almost 9% during the forecast period.

The advent of regenerative therapy

The global psoriatic arthritis therapeutics market currently faces a challenge due to the lack of curative therapies for the indication. As psoriatic arthritis is an autoimmune disorder, vendors in the market face a challenge in identifying the pathogenesis of the indication, which is acting as a barrier for the development of a potential cure for the indication. Various vendors and research organizations are conducting research on regenerative therapies such as stem cell therapy for curing psoriatic arthritis. Currently, approximately 25 genetic variants that are responsible for developing psoriatic diseases have been found, including psoriatic arthritis. Though these therapies are still in the early stages and are not expected to receive marketing approval during the forecast period, advances in research are expected to help in the identification of the pathogenesis and the cause of the indication, which can result in the market growth in the coming years.

For the detailed list of factors that will drive the global psoriatic arthritis therapeutics market during the forecast period 2019-2023, contact us.

Competitive Landscape

With the presence of a few major players, the global psoriatic arthritis therapeutics market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading psoriatic arthritis therapeutics manufacturers, that include AbbVie Inc., Celgene Corp., Johnson & Johnson Services Inc., Novartis AG, and Pfizer Inc.

Also, the psoriatic arthritis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc.
  • Celgene Corp.
  • Novartis AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers s
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Biologics - Market size and forecast 2018-2023
  • Small molecules - Market size and forecast 2018-2023
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Advent of regenerative therapy
  • Genetic screening tests
  • Increasing strategic alliances
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Celgene Corp.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
PART 16: EXPLORE AUTHOR

List of Exhibits
Exhibit 01:Product overview
Exhibit 02:Global pharmaceuticals market
Exhibit 03:Segments of global pharmaceuticals market
Exhibit 04:Market characteristics
Exhibit 05:Market segments
Exhibit 06:Market definition - Inclusions and exclusions checklist
Exhibit 07:Market size 2018
Exhibit 08:Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09:Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10:Five forces analysis 2018
Exhibit 11:Five forces analysis 2023
Exhibit 12:Bargaining power of buyers
Exhibit 13:Bargaining power of suppliers
Exhibit 14:Threat of new entrants
Exhibit 15:Threat of substitutes
Exhibit 16:Threat of rivalry
Exhibit 17:Market condition - Five forces 2018
Exhibit 18:Global psoriatic arthritis therapeutics market pipeline: Overview
Exhibit 19:Global psoriatic arthritis therapeutics market pipeline: Snapshot
Exhibit 20:Type - Market share 2018-2023 (%)
Exhibit 21:Comparison by type
Exhibit 22:Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23:Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 24:Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 25:Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 26:Market opportunity by type
Exhibit 27:Customer landscape
Exhibit 28:Market share by geography 2018-2023 (%)
Exhibit 29:Geographic comparison
Exhibit 30:North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31:North America - Year-over-year growth 2019-2023 (%)
Exhibit 32:Top 3 countries in North America
Exhibit 33:Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34:Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35:Top 3 countries in Europe
Exhibit 36:Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37:Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38:Top 3 countries in Asia
Exhibit 39:ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40:ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41:Top 3 countries in ROW
Exhibit 42:Key leading countries
Exhibit 43:Market opportunity
Exhibit 44:Humira biosimilars expected launch in the US
Exhibit 45:Impact of drivers and challenges
Exhibit 46:Vendor landscape
Exhibit 47:Landscape disruption
Exhibit 48:Vendors covered
Exhibit 49:Vendor classification
Exhibit 50:Market positioning of vendors
Exhibit 51:AbbVie Inc. - Vendor overview
Exhibit 52:AbbVie Inc. - Business segments
Exhibit 53:AbbVie Inc. - Organizational developments
Exhibit 54:AbbVie Inc. - Geographic focus
Exhibit 55:AbbVie Inc. - Key offerings
Exhibit 56:AbbVie Inc. - Key customers
Exhibit 57:Celgene Corp. - Vendor overview
Exhibit 58:Celgene Corp. - Business segments
Exhibit 59:Celgene Corp. - Organizational developments
Exhibit 60:Celgene Corp. - Geographic focus
Exhibit 61:Celgene Corp. - Key offerings
Exhibit 62:Celgene Corp. - Key customers
Exhibit 63:Johnson & Johnson Services Inc. - Vendor overview
Exhibit 64:Johnson & Johnson Services Inc. - Business segments
Exhibit 65:Johnson & Johnson Services Inc. - Organizational developments
Exhibit 66:Johnson & Johnson Services Inc. - Geographic focus
Exhibit 67:Johnson & Johnson Services Inc. - Segment focus
Exhibit 68:Johnson & Johnson Services Inc. - Key offerings
Exhibit 69:Johnson & Johnson Services Inc. - Key customers
Exhibit 70:Novartis AG - Vendor overview
Exhibit 71:Novartis AG - Business segments
Exhibit 72:Novartis AG - Organizational developments
Exhibit 73:Novartis AG - Geographic focus
Exhibit 74:Novartis AG - Segment focus
Exhibit 75:Novartis AG - Key offerings
Exhibit 76:Novartis AG - Key customers
Exhibit 77:Pfizer Inc. - Vendor overview
Exhibit 78:Pfizer Inc. - Business segments
Exhibit 79:Pfizer Inc. - Organizational developments
Exhibit 80:Pfizer Inc. - Geographic focus
Exhibit 81:Pfizer Inc. - Segment focus
Exhibit 82:Pfizer Inc. - Key offerings
Exhibit 83:Pfizer Inc. - Key customers
Exhibit 84:Validation techniques employed for market sizing
Exhibit 85:Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc.
  • Celgene Corp.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll